Aniket D. Kulkarni
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Aniket D. Kulkarni has a total of 27 co-authors. Here are the top co-authors by number of shared publications:
- Denise J. Jamieson
Department of Gynecology and Obstetrics, Emory University School of Medicine, Atlanta, GA
2 shared publications Dmitry M. Kissin
Women's Health and Fertility Branch, Division of Reproductive Health, National Center for Chronic Disease Prevention and Health Promotion, Centers for Disease Control and Prevention, Atlanta, GA
2 shared publicationsEli Y. Adashi
The Warren Alpert Medical School, Brown University, Providence, RI
2 shared publicationsEmilia H. Koumans
Division of Reproductive Health, Centers for Disease Control and Prevention, Atlanta, Georgia, USA
2 shared publicationsAnna W. Brittain
Division of Reproductive Health, Centers for Disease Control and Prevention, Atlanta, Georgia, USA
1 shared publication- Antoinette T. Nguyen
Division of Reproductive Health, National Center for Chronic Disease Prevention and Health Promotion, Centers for Disease Control and Prevention, Atlanta, Georgia
1 shared publication
Latest Publications
- 4 July 2024
- Published by SAGE Publications in Journal of Women's Health
- Vol. 33 (7) , 916-925
Claims for Contraceptive Services and Chlamydia and Gonorrhea Testing Among Insured Adolescent and Young Adult Females in the United States
Objective: To examine claims for reversible prescription contraceptives and chlamydia and gonorrhea testing among commercially and Medicaid-insured adolescent and young adult (AYA) females in the United States. Methods: Using IBM MarketScan Research Databases, we identified sexually active, nonpregnant AYA (15- to 24-year-old) females enrolled in 2018. We examined claims for reversible prescription contraceptives and chlamydia and gonorrhea testing, using drug names and diagnosis/procedure codes, by age-group in commercially and Medicaid-insured separately and by race/ethnicity in Medicaid-insured. Results: Among 15- to 19-year-old and 20- to 24-year-old females, 67.2% and 67.9% of commercially insured and 57.3% and 54.0% of Medicaid-insured, respectively, had claims for reversible prescription contraceptives in 2018. Across insurance types among both age-groups, the most common claim for contraceptives was prescription for combined oral contraceptives. Among Medicaid-insured 15- to 19-year-olds, claims for contraceptives ranged from 42.6% for Hispanic females to 63.4% for non-Hispanic White females; among Medicaid-insured 20- to 24-year-olds, claims ranged from 50.4% for non-Hispanic Black females to 57.0% for non-Hispanic White females. Approximately half of the commercially and Medicaid-insured females had claims for chlamydia and gonorrhea testing. Non-Hispanic Black females had the highest percentages of claims for chlamydia testing (56.3% among 15- to 19-year-olds and 61.1% among 20- to 24-year-olds) and gonorrhea testing (61.6% among 15- to 19-year-olds and 64.9% among 20- to 24-year-olds). Conclusion: Approximately, two-thirds of commercially insured and more than half of Medicaid-insured, sexually active, nonpregnant AYA females had claims for reversible prescription contraceptives. Race/ethnicity data were available for Medicaid-insured females, and there were differences in claims for contraceptives and chlamydia and gonorrhea testing by race/ethnicity. Half of the AYA females had claims for chlamydia and gonorrhea testing suggesting missed opportunities.
- 4 July 2024
- Published by SAGE Publications in Journal of Women's Health
- Vol. 33 (7) , 916-925
Claims for Contraceptive Services and Chlamydia and Gonorrhea Testing Among Insured Adolescent and Young Adult Females in the United States
Objective: To examine claims for reversible prescription contraceptives and chlamydia and gonorrhea testing among commercially and Medicaid-insured adolescent and young adult (AYA) females in the United States. Methods: Using IBM MarketScan Research Databases, we identified sexually active, nonpregnant AYA (15- to 24-year-old) females enrolled in 2018. We examined claims for reversible prescription contraceptives and chlamydia and gonorrhea testing, using drug names and diagnosis/procedure codes, by age-group in commercially and Medicaid-insured separately and by race/ethnicity in Medicaid-insured. Results: Among 15- to 19-year-old and 20- to 24-year-old females, 67.2% and 67.9% of commercially insured and 57.3% and 54.0% of Medicaid-insured, respectively, had claims for reversible prescription contraceptives in 2018. Across insurance types among both age-groups, the most common claim for contraceptives was prescription for combined oral contraceptives. Among Medicaid-insured 15- to 19-year-olds, claims for contraceptives ranged from 42.6% for Hispanic females to 63.4% for non-Hispanic White females; among Medicaid-insured 20- to 24-year-olds, claims ranged from 50.4% for non-Hispanic Black females to 57.0% for non-Hispanic White females. Approximately half of the commercially and Medicaid-insured females had claims for chlamydia and gonorrhea testing. Non-Hispanic Black females had the highest percentages of claims for chlamydia testing (56.3% among 15- to 19-year-olds and 61.1% among 20- to 24-year-olds) and gonorrhea testing (61.6% among 15- to 19-year-olds and 64.9% among 20- to 24-year-olds). Conclusion: Approximately, two-thirds of commercially insured and more than half of Medicaid-insured, sexually active, nonpregnant AYA females had claims for reversible prescription contraceptives. Race/ethnicity data were available for Medicaid-insured females, and there were differences in claims for contraceptives and chlamydia and gonorrhea testing by race/ethnicity. Half of the AYA females had claims for chlamydia and gonorrhea testing suggesting missed opportunities.
- 7 December 2023
- Published by Elsevier in Women's Health Issues
- Vol. 34 (2) , 186-196
Changes in Commercial Insurance Claims for Contraceptive Services During the Beginning of the COVID-19 Pandemic—United States, January 2019–September 2020
- 7 December 2023
- Published by Elsevier in Women's Health Issues
- Vol. 34 (2) , 186-196
Changes in Commercial Insurance Claims for Contraceptive Services During the Beginning of the COVID-19 Pandemic—United States, January 2019–September 2020
- 26 March 2022
- Published by Elsevier in Journal of Adolescent Health
- Vol. 71 (1) , 86-93
Trends in Emergency Contraceptive Use Among Adolescents and Young Adults, 2006–2017
- 26 March 2022
- Published by Elsevier in Journal of Adolescent Health
- Vol. 71 (1) , 86-93
Trends in Emergency Contraceptive Use Among Adolescents and Young Adults, 2006–2017
- 1 June 2019
- Published by Elsevier in Gynecologic Oncology
- Vol. 154, 142
Frailty as a predictor of delay in initiation of adjuvant chemotherapy treatment in women with ovarian cancer
- 1 June 2019
- Published by Elsevier in Gynecologic Oncology
- Vol. 154, 142
Frailty as a predictor of delay in initiation of adjuvant chemotherapy treatment in women with ovarian cancer
- 1 August 2017
- Published by Wiley in Paediatric and Perinatal Epidemiology
- Vol. 31 (5) , 438-448
Affordability of Fertility Treatments and Multiple Births in the United States
Background: Affordability plays an important role in the utilisation of in vitro fertilisation (IVF) and non‐IVF fertility treatments. Fertility treatments are associated with increased risk of multiple births. The objective of this study was to investigate the association between the affordability of fertility treatments across US states and the percentage of multiple births due to natural conception, non‐IVF treatments, and IVF, and the association between these percentages and state‐specific multiple birth rates.Methods: State‐specific per capita disposable personal income and state‐specific infertility insurance mandates were used as measures of affordability. Maternal age‐adjusted percentages of multiple births due to natural conception, non‐IVF treatments, and IVF were estimated for each state using birth certificate and IVF data. Scatter plots and regression analysis were used to explore associations between state‐level measures of affordability, the percentage of multiple births due to natural conception and fertility treatments, and state‐specific multiple birth rates.Results: In 2013, age‐adjusted contributions of natural conception, non‐IVF fertility treatments, and IVF to multiple births in US were 58.2, 22.8, and 19.0% respectively. States with greater affordability of fertility treatments had higher percentages of multiples due to IVF and lower percentages due to natural conception. Higher percentages of multiples due to IVF and lower percentages due to natural conception were associated with higher state‐specific multiple birth rates.Conclusion: Increasing affordability of fertility treatments may increase state‐specific multiple birth rates. Policies and treatment practices encouraging single‐gestation pregnancies may help reduce multiple births resulting from these treatments.
- 1 August 2017
- Published by Wiley in Paediatric and Perinatal Epidemiology
- Vol. 31 (5) , 438-448
Affordability of Fertility Treatments and Multiple Births in the United States
Background: Affordability plays an important role in the utilisation of in vitro fertilisation (IVF) and non‐IVF fertility treatments. Fertility treatments are associated with increased risk of multiple births. The objective of this study was to investigate the association between the affordability of fertility treatments across US states and the percentage of multiple births due to natural conception, non‐IVF treatments, and IVF, and the association between these percentages and state‐specific multiple birth rates.Methods: State‐specific per capita disposable personal income and state‐specific infertility insurance mandates were used as measures of affordability. Maternal age‐adjusted percentages of multiple births due to natural conception, non‐IVF treatments, and IVF were estimated for each state using birth certificate and IVF data. Scatter plots and regression analysis were used to explore associations between state‐level measures of affordability, the percentage of multiple births due to natural conception and fertility treatments, and state‐specific multiple birth rates.Results: In 2013, age‐adjusted contributions of natural conception, non‐IVF fertility treatments, and IVF to multiple births in US were 58.2, 22.8, and 19.0% respectively. States with greater affordability of fertility treatments had higher percentages of multiples due to IVF and lower percentages due to natural conception. Higher percentages of multiples due to IVF and lower percentages due to natural conception were associated with higher state‐specific multiple birth rates.Conclusion: Increasing affordability of fertility treatments may increase state‐specific multiple birth rates. Policies and treatment practices encouraging single‐gestation pregnancies may help reduce multiple births resulting from these treatments.
- Top Cited Papers
- 5 December 2013
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 369 (23) , 2218-2225
Fertility Treatments and Multiple Births in the United States
The advent of fertility treatments has led to an increase in the rate of multiple births in the United States. However, the trends in and magnitude of the contribution of fertility treatments to the increase are uncertain.
- 5 December 2013
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 369 (23) , 2218-2225
Top Cited PapersFertility Treatments and Multiple Births in the United States
The advent of fertility treatments has led to an increase in the rate of multiple births in the United States. However, the trends in and magnitude of the contribution of fertility treatments to the increase are uncertain.